Beta-amyloid-analogue - t-cell epitope vaccine
CA 2457140 C · Owner: Rasmussen, Peter Birk · Inventors: Rasmussen, Peter Birk; Nielsen, Klaus Gregorius; Koefoed, Peter
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protein (APP) or beta amyloid (A.beta.). Immunization is preferably effected by administration of analogues of autologous APP or A.beta. said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A.beta. which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against APP or A.beta. and vaccination using live …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 20, 2002 and granted August 5, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 20, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 20, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.